P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
AssigneesThe United States of America as represented by the Department of Health and Human Services, Merial Limited
InventorsJesus G. Valenzuela, Jose M. C. Ribiero, Shaden Kamhawi, Yasmine Belkaid, Laurent Fischer, Jean-Christophe Audonnet, Francis Milward
Life of this patent
Estimating the term…
Abstract
Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating or preventing Leishmaniasis are disclosed.
Claims10
A substantially purified salivary Phlebotomus ariasi polypeptide, wherein the polypeptide comprises:
- a) residues 23-312 of the SEQ ID NO:
- 11;
- b) an amino acid sequence that is at least 95% identical to residues 23-312 of SEQ ID NO:
- 11;
- or c) an immunogenic fragment comprising at least fifteen contiguous amino acids of residues 23-312 of SEQ ID NO:
- 11.
A substantially purified salivary Phlebotomus ariasi polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to residues 23-312 of SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.